International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative.

MLA

Oldroyd, Alexander G. S., et al. “International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: An International Myositis Assessment and Clinical Studies Group (IMACS) Initiative.” Nature Reviews. Rheumatology, vol. 19, no. 12, Dec. 2023, pp. 805–17. EBSCOhost, https://doi.org/10.1038/s41584-023-01045-w.

APA

Oldroyd, A. G. S., Callen, J. P., Chinoy, H., Chung, L., Fiorentino, D., Gordon, P., Machado, P. M., McHugh, N., Selva-O’Callaghan, A., Schmidt, J., Tansley, S. L., Vleugels, R. A., Werth, V. P., & Aggarwal, R. (2023). International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative. Nature Reviews. Rheumatology, 19(12), 805–817. https://doi.org/10.1038/s41584-023-01045-w

Chicago

Oldroyd, Alexander G S, Jeffrey P Callen, Hector Chinoy, Lorinda Chung, David Fiorentino, Patrick Gordon, Pedro M Machado, et al. 2023. “International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: An International Myositis Assessment and Clinical Studies Group (IMACS) Initiative.” Nature Reviews. Rheumatology 19 (12): 805–17. doi:10.1038/s41584-023-01045-w.